Meet SlateXpace™, CRB’s latest solution
Sep 30, 2020
Meet SlateXpace™ – a multimodal facility solution that delivers unmatched industry speed, flexibility and adaptability for the advanced therapy market.
CRB’s SlateXpaceTM gives cell and gene therapy clients new flexibility, control over manufacturing needs to support highly complex product pipelines.
Emerging health threats, uncured diseases and the need to deliver critical therapies to patients are driving biotech companies to search for ways to build flexibility into their complex product pipelines and deliver projects in record time. Today, a pioneering multimodality manufacturing solution addresses that challenge: SlateXpace™.
SlateXpace™ (pronounced “Slate Space”) is a CRB solution that breaks from conventional facility design by providing unparalleled flexibility, speed to market and budget control, allowing companies to quickly deliver multiple novel therapies to patients. Clients get a customizable, time and cost-efficient solution that accommodates rapidly evolving multi-modal pipelines while future proofing their capital investments. They also get peace of mind as SlateXpace™ leverages the expertise and capabilities of a team that manages every detail end to end – from facility fabrication and delivery, equipment selection and installation, to start-up, qualification and operator training.
The agility at the heart of SlateXpace’s mission heralds a critical turning point in the story of advanced therapy medicinal product (ATMP) manufacturing. The 1980s biotech explosion, the advent of stainless–steel facilities, and the arrival of closed processing technology and eventually ballroom manufacturing concepts each ushered periods of uncomfortable adjustment – followed soon by untapped potential. Today, biotechnology companies are navigating the next scientific breakthrough with the promises brought on by the rise of cell and gene therapy products. However, many operators remain constrained by technologies and processes ill-suited for a fast-shifting market.
SlateXpace™ seizes on that potential by giving clients full operational turnkey delivery, upfront cost and schedule confidence and infinite flexibility, allowing clients to capture new markets or take advantage of emerging technologies. Implementing SlateXpace™ facilities allows you to constantly transform and grow with your business to address rapidly evolving market demands.
Drawing on CRB’s more than 35 years of life sciences experience, SlateXpace’s unique suite-based platform moves ATMP manufacturing beyond off-the-shelf cleanroom boxes and into a new era that empowers clients to shift flexibly, quickly and seamlessly between therapies. Using SlateXpace™, an operator could run a product campaign in one modality, decontaminate that space, swap out single-use and mobile equipment and run a new batch in the same space – in a different modality – all within a few weeks.
Modalities currently test-fitted for SlateXpace include vaccines, monoclonal antibodies (mAbs), viral vectors, plasmids, allogeneic cell therapies and autologous cell therapies as well as the potential to accommodate other future biotech modalities – an “X” factor that can accommodate bespoke client designs, new technologies or unforeseen scientific breakthroughs.